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ABSTRACT   RAS -associated autoimmune leukoproliferative disorder (RALD) is a recently 
reported rare nonmalignant autoimmune disorder. The characteristic clinical findings of RALD 
include monocytosis, leukocytosis, lymphoproliferation, and autoimmune phenomena. RALD 
is defined by somatic mutations in KRAS or NRAS. It is a new disease that was reported by 
Niemela and Takagi in 2011. The prognosis and incidence are currently unknown and the 
treatment strategy has not yet been established.
   Here we describe the long-term survival of a patient with who displayed a somatic KRAS 
G12D mutation. His clinical features and labolatory data were overlapped with juvenile 
myelomonocytic leukemia and chronic myelomonocytic leukemia. Mercaptopurine hydrate, 
hydroxycarbamide and azacitizine were administered to control white blood cell count and 
improve clinical symptoms. He had a long survival time without hematopoietic stem cell 
transplantation. doi：10.11482/KMJ-E201945009　(Accepted on May 11, 2019)
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(CMML), and autoimmune lymphoproliferative 
syndrome (ALPS)３－５）. 
   RALD is caused by activation of RAS-family 
proteins, including NRAS and KRAS. KRAS is a gene 
that acts as an on/off switch for cell signaling. When 
it functions normally, it controls cell proliferation. 
When it is mutated, negative signaling is disrupted. 
Therefore, cells can continuously proliferate and 
often develop into cancers. The prognosis of RALD 
is unknown because there are very few cases３－５）.
   We observed the long-term survival of a patient 
INTRODUCTION
   RAS-associated autoimmune leukoproliferative 
disorder (RALD) is a chronic, non malignant 
condition that characterized by monocytosis, 
leukocytosis, lymphoproliferation, and autoimmune 
phenomena. RALD is a new class of monogenic 
autoimmune diseases１，２）.
   Patients with RALD show overlap of clinical 
features  and laboratory data  with pat ients 
w i t h  j u v e n i l e  m y e l o m o n o c y t i c  l e u k e m i a 
(JMML), chronic myelomonocytic leukemia 
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Fig. 1. Physical examination at the age of 18 years
Table 1. Laboratory findings on admission
Peripheral blood Blood chemistry Bone marrow
WBC 34,540 /μl TP 8.2 g/dl NCC 28.2×104 /μl
　Neut 73 % Alb 2.4 g/dl Megk 69.4 /μl
　Lym 2 % T.Bil 1.3 mg/dl Blast 0.2 %
　Mon 25 % AST 39 U/l Eo 0.6 %
　Eos 0 % ALT 17 U/l Baso 0.2 %
　Baso 0 % LDH 470 U/l Myeloid series 47.4 %
RBC 264×104 /μl ALP 1116 U/l Mono 22.2 %
Hb 9.0 g/dl γ-GTP 333 U/l Erythroid series 15.8  
HbF 1.0 g/dl BUN 17 mg/dl
Ht 27.6 % Cr 0.21 mg/dl Chromosome G-banding
MCV 104.5 fl UA 4.7 mg/dl 47, XY, +8  [20/20]
MCH 34.1 pg Glu 96 mg/dl
Plt 24.7×104 /μl CRP 6.41 mg/dl Spontaneous colony (-)
Na 128 mEq/l GM-CSF hypersensitivity (-)
Coaglation K 2.9 mEq/l
PT 9.3 sec Cl 90 mEq/l
APTT 33.0 sec Ca 7.8 mg/dl





with RALD who displayed a somatic KRAS G12D 
mutation.
CASE REPORT
     A 6 month-old boy presented with bilateral 
cervical lymphoadenopathy, splenomegaly, and 
moderate anemia. Bone marrow (BM) aspiration 
and a trephine biopsy were performed. His BM 
revealed normocellular marrow with evident 
erythrodysplasia and 2% blasts involving trisomy 
8. The patient was diagnosed with myelodysplastic 
syndrome (MDS). His parent refused hematopoietic 
stem cell transplantation (HSCT), and he remained 
under observation with red blood cell concentrate 
transfusion. At the age of 13 years, he had a 
remarkably short stature of -5.3 SD and a low 
weight of -3.0 SD (Fig. 1).
   He had taken mercaptopurine hydrate to control 
his splenomegaly since the  age of 6 years, but his 
splenomegaly gradually worsened, and put pressure 
on his gastrointestinal tract. By the age of 13 years, 
he was unable to consume food because of the 
Figure 1




























Fig. 2. Clinical course
The fever describes the peak temperature.
6MP: mercaptopurine hydrate, HU: hydroxycarbamide, AZA: azacitizine
splenomegaly. He underwent a splenectomy, and 
the pressure on the intestinal tract was reduced. 
However, a hematological examination showed a 
white blood cell (WBC) count of 31,300 - 121,800/
µL with monocytosis (2,308 - 29,841/µL) . 
   His serum levels of immunoglobulin (Ig) G, 
IgA, and IgM were 2,780, 1,398 and 481 mg/dL, 
respectively. His antinuclear antibodies were mildly 
positive, and his HbF did not increase (Table 1).
   He presented with fever, rash, and arthralgia 
because of the WBC count increase; hydroxycarbamide 
was used to control his WBC count. Rashes 
appeared as small red bumps on his arms, legs, 
neck, and trunk were associated with pain; therefore 
we diagnosed Sweet’s syndrome. Treatment with 
a corticosteroid was effective, but the rashes 
recurred frequently. He also had deafness in his 
right ear at the age of 14 years, and his hearing 
loss was irreversible (Fig. 2). A peripheral blood 
smear evaluation  showed absolute monocytosis 
with 1% circulating blast. An assessment of his 
BM revealed severe hyperplasia, monocytosis, and 
dysplasia with megaloids, micromegakaryocytes, 
ringed neutrophils, and hypersegmented neutrophils 
(Fig. 3). However, BM contained only 1% blasts 
involving trisomy 8. The Spontaneous colony 
and GM-CSF hypersensi t ivi ty assessments 
were negative. Therefore, we diagnosed CMML 
transformed from MDS. 
   To reduce leukocytosis and improve clinical 
symptoms, he was administered six cycles of 
azacitizine (AZA) (75  mg/m2 ,  day1-5 ,  each 
cycle every 4 weeks) at the age of 17 years. The 
percentage of bone marrow blasts did not change 
from 1% to 2% before and after AZA. All cell 
line did not reach normal maturation. Complete 
remission was not achieved, but his clinical data and 
symptoms improved. The white blood cell count 
decreased and hepatomegaly was reduced. The fever 
was relieved and the rash with pain disappeared 
(Fig. 2). Following this, a somatic KRAS c.35 G>A 
mutation was found, and he was diagnosed with 
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RALD (Fig. 4). Other JMML and ALPS related 
gene mutations were not detected.
   The patient died due to liver failure at the age of 
19 years.
DISCUSSION
   RALD is a rare disease caused by a RAS 
pa thway  muta t ion .  I t  i s  cha rac te r i zed  by 
lymphoproliferation with an increase of CD4-
CD8- double negative T cells. The clinical features 
includes monocytosis, leukocytosis, splenomegaly, 
and hypergammaglobulinemia１，２）. Furthermore, 
in some patients, this disease occurs in combination 
with autoimmune diseases such as systemic 
lupus erythematosus, Rosai-Dorfman syndrome, 
and Sweet’s syndrome６，７）. In some patients, an 
increase in HbF and GM-CSF hypersensitivity has 
been confirmed. RALD is caused by the activation 
of RAS-family proteins, including NRAS and KRAS. 
RALD is considered a disease that shares some 
Figure 4
KRAS Exon2
Fig.  4 .  (A)Bone marrow from the patient  showing 
micromegakaryocytes (× 400)
(B) Bone marrow from the patient showing megaloids (×
1,000)
(C) Bone marrow from the patient showing hypersegmented 
neutrophils and ringed neutrophils (×1,000)
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Fig. 5. Comparison of pathologies of JMML, RALD and ALPS 
clinical features and molecular genetic abnormalities 
with other leukoproliferative diseases, such as 
ALPS, JMML, and CMML (Fig. 5). Several cases 
have been reported, but the prognosis and standard 
treatment remain unclear. RALD is a slow disease, 
but some cases have been reported with rapid 
progression and pulmonary infiltration３－５）.
   Allogenic HSCT is the only treatment for patients 
with RALD. However, one opinion recommends 
avoiding aggressive interventions, such as HSCT, 
in patients with RALD without clear evidence of 
malignancy５）. Toyoda et al reported that rituximab 
could improve the clinical response and quality of 
life of patients with RALD８）.
   For our patient, we administered mercaptopurine 
hydrate, hydroxycarbamide, and AZA for improving 
the clinical symptoms and suppressing the WBC 
count before RALD was diagnosed.  
   Hypomethylating drugs are useful for the 
management of MDS and CMML９，10）. Costa et 






























36) when AZA was administered to patients with 
CMML９）. The disorder did not reach remission with 
AZA treatment, but the condition remained stable, 
and some improvements in clinical symptoms were 
observed. Accumulation of the use experience for 
children is expected in the future.
   Our report has several limitations. We did not 
estimate the TCRαβ+CD4-CD8- double negative 
T cell and conduct an apoptosis assay. Therefore, 
differentiation from other autoimmune diseases such 
as ALPS and JMML, may be difficult. 
   Transformation from MDS to CMML is rarely 
observed. After being diagnosed with MDS at the 
age of 6 months based on BM examination, the 
patient did not undergo a splenectomy until the 
age of 13 years because his parents did not want 
invasive treatment. Therefore, the evaluation of 
disease activity may have been insufficient. 
   In summary, we report the long-term survival of a 
patient with RALD with a somatic KRAS mutation. 
The pathological condition and prognosis of RALD 
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have not yet been elucidated, and further study of 
cases is necessary.
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